SVB Leerink Maintains Outperform on InflaRx, Lowers Price Target to $4
SVB Leerink analyst Joseph Schwartz maintains InflaRx (NASDAQ:IFRX) with a Outperform and lowers the price target from $6 to $4.
InflaRx Shares Plunge After Disappointing Results On Vilobelimab In Critically Ill COVID-19 Patients
InflaRx N.V. (NASDAQ:IFRX) announced topline data from Phase 3 part of Phase 2/3 PANAMO study of vilobelimab in critically ill COVID-19…
InflaRx Announces Phase III Topline Results From PANAMO Trial Of Vilobelimab In Severe COVID-19 Patients; Co. Reports Trial Did Not Show Statistical Significance On The Pre-specified Primary Endpoint
Vilobelimab treatment results in relative reduction in 28-day all-cause mortality of 23.9% compared to placebo (p-value=0.094), but did not show statistical significance on the pre-specified primary
10 Biggest Price Target Changes For Friday
Jefferies cut the price target on MEI Pharma, Inc. (NASDAQ: MEIP) from $4 to $1. MEI Pharma shares fell 44.2% to $1.01 in pre-market trading.
Recap: InflaRx Q4 Earnings
InflaRx (NASDAQ:IFRX) reported its Q4 earnings results on Thursday, March 24, 2022 at 07:30 AM.
Here's what investors need to know about the announcement.
The Week Ahead In Biotech (March 20-26): Focus On Zogenix FDA Decision, Dermatology Conference Presentations & Earnings
Biotech stocks rebounded along with the broader market in the week ending March 18, as risk appetite returned. Multiple conference presentations, clinical readouts and earnings news dictated sentiment during the week.